Research · Sep 3, 2026
[BLCO] Bausch + Lomb Thesis 2026: Contact Lenses, Miebo and Xiidra Anchor an Eye-Health Pure-Play Awaiting Independence
Bausch + Lomb Corporation (NYSE/TSX: BLCO) is a Vaughan, Ontario, Canada-headquartered (operational HQ in Bridgewater, New Jersey) leading pure-play eye-health company — founded 1853 in Rochester, New York, with a multi-century history of pioneering vision products (the soft contact lens, Vaseline, ReNu lens-care solutions; Ray-Ban divested 1999). The modern company is the eye-health business of the former Valeant Pharmaceuticals (Valeant acquired Bausch + Lomb 2013, rebranded as Bausch Health (BHC) 2018, and spun off Bausch + Lomb as a separately-listed entity in May 2022 — first step toward a full separation contingent on BHC's debt-leverage conditions). As of FY2025 BHC still owns ~88% of BLCO — the full separation has been delayed due to BHC's heavy debt (~$20B+) and Xifaxan patent-cliff uncertainty — leaving BLCO a publicly-listed but parent-controlled company with the separation question a persistent overhang. Three reporting segments: Vision Care (~half-ish — contact lenses Biotrue, PureVision, INFUSE, Bausch + Lomb Ultra and the SiHy daily family plus lens-care Biotrue/ReNu and consumer/OTC eye care Lumify and PreserVision); Pharmaceuticals (~⅓ — Miebo (perfluorohexyloctane, first-and-only US-approved water-free dry-eye drug, launched late 2023) and Xiidra (lifitegrast, acquired from Novartis 2023 for ~$1.75B), plus Lotemax, glaucoma, legacy Rx); Surgical (~the remaining portion — IOLs incl. the enVista family, Stellaris vitreoretinal and phaco platforms, instruments/consumables). Geography is global with a US lead. BLCO enters FY2026 with FY2025 revenue selected various aggregate ~$4.9-5.3B, aggregate adjusted EPS ~$0.30-1.10 (GAAP loss likely), adjusted EBITDA ~$850M-1.05B (~17-20% margin), under Chairman & CEO Brent Saunders (~2-3 year tenure since 2023). The first thesis pillar bundles Vision Care plus Pharmaceuticals — together producing most of revenue and growth: Vision Care is the consumer franchise built on contact lenses and lens care plus consumer-OTC eye care — contact lenses the core (a comprehensive portfolio across modality: monthly silicone-hydrogel Bausch + Lomb Ultra and PureVision, two-week lenses, silicone-hydrogel daily disposables INFUSE and INFUSE One Day family — the high-growth daily SiHy category plus toric and multifocal versions — and lens-care solutions Biotrue multipurpose, ReNu — sold through eye-care professionals and online); the SiHy daily segment is the fastest-growing contact-lens category and the most contested (Alcon's Total1, J&J's Acuvue Oasys 1-Day with HydraLuxe, CooperVision's MyDay, plus INFUSE One Day) — share gains here are the headline Vision Care KPI; consumer eye care / OTC — Lumify (brimonidine red-eye drop, category-defining, strong margins, growing distribution), PreserVision (AREDS/AREDS2 vitamins for AMD), various OTC; Pharmaceuticals — anchored by Miebo (perfluorohexyloctane ophthalmic solution — the first-and-only US-approved water-free dry-eye drug, designed to address tear-film evaporation rather than just inflammation — launched late 2023, ramping into a large DED market) and Xiidra (lifitegrast 5% — an LFA-1 antagonist for inflammatory dry eye, acquired from Novartis 2023 for ~$1.75B) — a two-drug dry-eye franchise competing against Restasis (generic), Cequa (Sun Pharma), Tyrvaya (Viatris/Oyster Point), Vevye (Harrow) and OTC — plus legacy Rx eye drops (Lotemax, glaucoma); FY2025 dynamics are contact-lens revenue growing mid-single-digit (daily SiHy uptake), Lumify outperforming, Miebo ramping faster than initial expectations, Xiidra growth post-acquisition, favorable pricing/mix, steady segment margin; FY2026 catalyst is Miebo prescription growth and reimbursement, Xiidra hold-or-gain, INFUSE daily SiHy growth and extensions, Lumify line extensions, contact-lens-care steady, and any new Rx launches; risks/competitors are contact-lens share losses to Alcon (ALC), Johnson & Johnson Vision (JNJ), CooperVision (COO), dry-eye competition (Sun Pharma Cequa, Viatris/Oyster Point Tyrvaya, Harrow Vevye), generic erosion of legacy Rx, payer pricing pressure, OTC competition for Lumify, US tariff/trade dynamics on imported contact lenses. The second pillar is Surgical plus the BHC parent overhang: Surgical (~15-20% of revenue) — IOLs anchored by the enVista family (a premium hydrophobic-acrylic IOL platform with monofocal, toric and newer enVista multifocal/EDOF — competing against Alcon's AcrySof/Vivity/PanOptix, J&J Vision's Tecnis/Symfony/Synergy, plus Carl Zeiss Meditec, HOYA, Rayner — the multifocal/EDOF segment the fastest-growing IOL category); surgical equipment (Stellaris vitreoretinal + Stellaris Elite phaco platforms + visualization + instruments + consumables — equipment placements driving consumable pull-through); FY2025 dynamics are cataract-volume growth, mixed Surgical revenue (IOL share dynamics, equipment placements steady), enVista launch progress; FY2026 catalyst is the enVista IOL family (especially multifocal/EDOF — share-gain potential), equipment placements, cataract-volume backdrop, and pricing/mix; risks/competitors are Alcon (ALC, dominant IOL leader), J&J Vision (JNJ), Carl Zeiss Meditec (CZMWY), HOYA, regional/Chinese players. The BHC parent overhang — BHC still owns ~88% of BLCO common stock; the originally-planned full separation has been repeatedly delayed as BHC has wrestled with substantial debt (~$20B+) and the Xifaxan patent-cliff uncertainty (Xifaxan, BHC's largest drug, has faced generic challenges litigated extensively); the separation outcome is a structural BLCO equity overhang and an upside lever (a full BHC spin-off would remove parent-control overhang and unlock institutional ownership; alternatively, a sale of BLCO at a premium has been speculated); FY2026 catalyst is any movement on the full separation (BHC's debt situation, Xifaxan resolution, distribution decision) — a significant binary; risks are continued delay (overhang persists) or an unfavorable separation structure tying BLCO to BHC liabilities. Comp set: Alcon (ALC) the closest pure-play eye-health comp, J&J Vision (JNJ), Cooper (COO), Carl Zeiss Meditec (CZMWY), HOYA, dry-eye Viatris (VTRS), Harrow (HROW), Sun Pharma (SUNPHARMA.NS), consumer eye-drop Procter & Gamble (PG). The capital story: no dividend and no buybacks (cash to debt service, R&D and commercial investment — especially Miebo + Xiidra build-out), net debt ~$4.0-4.6B (term loans + senior notes + ABL/revolver — the Xiidra acquisition added ~$1.75B+ of debt), ~5-7x net debt/EBITDA (high — a concern for the equity story), sub-investment-grade credit profile (B+/B1-area at the major agencies), free cash flow modest given the rate cycle and Xiidra-related working-capital build (inflecting positive as Miebo/Xiidra revenue scales and as interest expense ideally moderates with rate cuts), FCF priorities debt service + debt paydown + growth investment, ~355-365M shares (BHC owns ~88%), and the BHC parent overhang dominating the balance-sheet considerations along with the high leverage, the Xiidra debt service, rate sensitivity, the BHC separation outcome, refinancing risk on upcoming maturities, and the question of when FCF inflects materially. At ~$14-22 per share on ~355-365M shares (~$5-8B equity, ~$9-12.5B EV) BLCO trades at roughly ~10-15x EV/EBITDA — best framed on EV/Sales (~1.7-2.5x) versus eye-health peers — a discount to the premium pure-play Alcon reflecting higher leverage, the BHC parent overhang, no capital returns, and a less-than-best-in-class growth/margin profile — versus Alcon (ALC, the direct read-through at premium multiples), Cooper Companies (COO), Carl Zeiss Meditec (CZMWY), HOYA, Johnson & Johnson (JNJ, J&J Vision within Medtech), Viatris (VTRS), Harrow (HROW), Sun Pharma (SUNPHARMA.NS) on dry eye, Procter & Gamble (PG) and OTC players on consumer eye care. FY2026 base case: ~$5.2-5.6B revenue + ~$0.50-1.30 adj. EPS + ~$900M-1.1B adjusted EBITDA + Miebo + Xiidra ramping + INFUSE growth + enVista launching + leverage stable-to-down + BHC overhang unresolved — solid revenue growth, slow deleveraging; bull case: ~$5.5-6.0B+ revenue + ~$1.00-2.00+ adj. EPS on Miebo exceeding expectations, Xiidra outperforming, INFUSE One Day SiHy taking share, enVista multifocal/EDOF launching strongly, margin expansion, FCF inflecting, a full BHC spin-off completed removing the overhang and re-rating the stock, deleveraging accelerating, and a re-rating toward ALC-style multiples; bear case: ~$4.7-5.1B revenue + ~$(0.30)-0.30 adj. EPS on Miebo/Xiidra disappointing, contact-lens share losses, enVista launch missing, surgical-equipment softness, leverage rising, BHC separation stalling, and a de-rating. The thesis depends on the Vision Care + Pharmaceuticals pipeline (contact lenses + Lumify + Miebo + Xiidra + INFUSE daily SiHy + dry-eye franchise) plus the Surgical + BHC pipeline (enVista IOL + Stellaris equipment + the parent-separation outcome + leverage path) plus the dry-eye and silicone-hydrogel-daily growth backdrops plus deleveraging plus the binary BHC separation catalyst plus Brent Saunders's execution of the post-spin eye-health pure-play playbook.